Solid Biosciences Inc. (SLDB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Solid Biosciences Inc. (SLDB) closed at USD 5.47 on 2026-10-14, a change of -7.7 % over the past year, with a market capitalization of USD 615.47M.

Solid Biosciences Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Solid Biosciences Inc. key figures

Previous close

USD 5.47 (2026-10-14)

1-year change

-7.7 %

Market cap

USD 615.47M

Enterprise value

USD 257.95M

P/E ratio (trailing)

-3.07

P/E ratio (forward)

-3.36

EPS (trailing)

-1.87

EPS (forward)

-1.71

PEG ratio

n/a

Price to book

1.61

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.04

Employees

121

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Solid Biosciences Inc.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Solid Biosciences Inc. and compare it with other stocks.